id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-298866-dzatps7b	Licskai, Christopher	Key highlights from the Canadian Thoracic Society’s Position Statement on the Optimization of Asthma Management during the COVID-19 Pandemic	2020-05-28		.txt	text/plain	1545	94	48	title: Key highlights from the Canadian Thoracic Society's Position Statement on the Optimization of Asthma Management during the COVID-19 Pandemic In general, asthma maintenance and exacerbation management should continue according to national and international guidelines during the COVID-19 pandemic, however treatment decisions should be individualized based on patient characteristics. 6, 7, 8 Are patients with asthma at risk of having an exacerbation triggered by SARS-CoV-2 (COVID 19)? The Centers for Disease Control identify people with asthma as a group that may be at higher risk for severe illness from COVID-19. No. Asthma patients should restart or continue their prescribed inhaled corticosteroid or inhaled corticosteroid steroid plus long-acting beta 2 -agonist maintenance therapy to improve disease control and to reduce the severity of exacerbations, including exacerbations that may be caused by SARS-CoV-2. Yes. There is no evidence that inhaled corticosteroids increase the risk of acquiring COVID-19 or that inhaled corticosteroids increase the severity of infection.	./cache/cord-298866-dzatps7b.txt	./txt/cord-298866-dzatps7b.txt